Here are the 424B prospectus supplements from Amesite Inc. (AMST) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AMST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMST filings page.
Amesite Inc., an AI-focused healthcare technology company, established an at-the-market equity program with H.C. Wainwright & Co. to sell up to $2,266,112 of common stock from time to time. Shares may be sold on Nasdaq under the symbol AMST, with Wainwright acting as sales agent and earning a 3.0% commission on gross proceeds.
As of March 31, 2026, common shares outstanding were 4,748,001, and assuming sales of 1,970,532 shares at an illustrative price of $1.15, shares outstanding would rise to 8,520,383. At that assumed level, as adjusted net tangible book value would increase to $0.34 per share, implying immediate dilution of $0.81 per share to new investors. Amesite plans to use any net proceeds for general corporate and working capital purposes while warning that investing in its stock involves a high degree of risk and that it does not anticipate paying cash dividends.
Amesite Inc. is offering 696,866 shares of common stock at an offering price of $1.435 per share pursuant to this prospectus supplement, with expected gross proceeds of approximately $1.0 million. The offering is being conducted with H.C. Wainwright & Co. as exclusive placement agent and closes subject to customary conditions.
Concurrently, Amesite is conducting a private placement of Pre-Funded Warrants and two series of unregistered common stock warrants (Series A-1 and Series A-2) to the purchasers under the Securities Purchase Agreement dated April 27, 2026. Certain directors (including the CEO) are participating in the Private Placement on the same economic terms, and the Audit Committee and Board approved those related-party investments.